Drug class | HIVDR Mutation (n = 16) | Treatment Naive (n = 5) | ART experienceda (n = 11) | Total (n = 16) |
---|---|---|---|---|
NNRTI | K103N/S | 3 (60.0%) | 4 (36.4%) | 7 (43.8%)b |
A98G | 0 (0.0%) | 2 (18.2%) | 2 (12.5%) | |
E1238A | 0 (0.0%). | 1 (9.1%) | 1 (6.3%) | |
K238N | 0 (0.0%) | 1 (9.1%) | 1 (6.35) | |
K238T | 0 (0.0%) | 1 (9.1%) | 1 (6.3%) | |
P225H | 0 (0.0%) | 1 (9.1%) | 1 (6.3%) | |
V106A | 0 (0.0%) | 1 (9.1%) | 1 (6.3%) | |
V179E | 0 (0.0%) | 1 (9.1%) | 1 (6.3%) | |
Y188H | 0 (0.0%) | 1 (9.1%) | 1 (6.3%) | |
Y188L | 1 (20.0%) | 0 (0.0%) | 1 (6.3%) | |
NRTI | M184V | 0 (0.0%) | 6 (54.5%) | 6 (37.5%)b |
M41L | 1 (20.0%) | 1 (9.1%) | 2 (12.5%) | |
T215Y | 0 (0.0%) | 2 (18.2%) | 2 (12.5%) | |
D67N | 1 (20.0%) | 0 (0.0%) | 1 (6.3%) | |
E44D | 0 (0.0%) | 1 (10.0%) | 1 (6.3%) | |
K219E | 1 (20.0%) | 0 (0.0%) | 1 (6.3%) | |
T215FY | 0 (0.0%) | 1 (9.1%) | 1 (6.3%) | |
T215I | 1 (20.0%) | 0 (0.0%) | 1 (6.3%) | |
PI | L89V | 0 (0.0%) | 1 (9.1%) | 1 (6.3%)b |